Tech Company Financing Transactions
Artiva Biotherapeutics Funding Round
On 3/2/2021, Artiva Biotherapeutics raised $120 million in investment from Venrock, 5AM Ventures and RA Capital.
Transaction Overview
Company Name
Announced On
3/2/2021
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Investors
Venrock (Lead Investor)
5AM Ventures (Brian Daniels)
RA Capital (Laura Stoppel)
venBio (Yvonne Yamanaka)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4747 Executive Dr. 1150
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva's platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Fred Aslan
Chief Financial Officer
Esther van den Boom
Chief Medical Officer
Jason Litten
Chief Operating Officer
Peter Flynn
Vice President
Heather Raymon
Vice President
Sungyong Won
VP - Bus. Development
Thomas Farrell
VP - General Counsel
Jennifer Bush
VP - Human Resources
Anne Frese
VP - Operations
John Lim
VP - Regulatory Affairs
Eugene Helsel
Browse more venture capital transactions:
Prev: 3/2/2021: Tenaya Therapeutics venture capital transaction
Next: 3/2/2021: Skydio venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs